Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aligos Therapeutics, Inc.

4.62
-0.0600-1.28%
Post-market: 4.620.00000.00%16:05 EDT
Volume:111.36K
Turnover:513.41K
Market Cap:28.25M
PE:-0.22
High:4.83
Open:4.54
Low:4.43
Close:4.68
Loading ...

Mirum’s LIVMARLI Now FDA Approved in Tablet Formulation

Business Wire
·
14 Apr

Aligos Therapeutics Inc Files For Offering Of Up To 6.2 Million Common Shares By The Selling Securityholders - SEC Filing

Reuters
·
28 Mar

Aligos Therapeutics files to sell 6.25M shares of common stock for holders

TIPRANKS
·
28 Mar

Aligos Therapeutics Inc Files for Offering of up to 6.2 Mln Common Shares by the Selling Securityholders - SEC Filing

THOMSON REUTERS
·
28 Mar

LIVMARLI Now Approved in Japan for ALGS and PFIC

Business Wire
·
27 Mar

Ten option delistings on March 24th

TIPRANKS
·
24 Mar

Aligos Therapeutics Faces Challenges in Developing Hepatitis B Treatments Amidst Industry Competition

TIPRANKS
·
12 Mar

Aligos Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
11 Mar

Aligos Therapeutics Advances Pipeline Amid Financial Challenges

TIPRANKS
·
11 Mar

Nasdaq, S&P 500 Hit 6-Month Lows As Recession Fears Grow: What's Driving Markets Monday?

Benzinga
·
11 Mar

Aligos Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
11 Mar

BUZZ-Aligos Therapeutics falls on bigger Q4 loss

Reuters
·
11 Mar

BRIEF-Aligos Therapeutics reports fourth-quarter and full-year 2024 results

Reuters
·
10 Mar

Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Lags Revenue Estimates

Zacks
·
10 Mar

Aligos Therapeutics Q4 EPS $(13.08) Misses $(2.30) Estimate, Sales $629.00K Beat $433.33K Estimate

Benzinga
·
10 Mar

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire
·
10 Mar

Aligos Therapeutics Inc expected to post a loss of $2.50 a share - Earnings Preview

Reuters
·
07 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
05 Mar

Aligos Therapeutics to Announce 4th Quarter 2024 Financial Results on March 10, 2025

GlobeNewswire
·
03 Mar

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

Business Wire
·
27 Feb